SCHEMBL17075097

SCHEMBL17075097

c1ccc(CN2CCC(C3CCC3)c3ccccc32)cc1

nearest known ligand 0.45

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SIGMAR1 Q99720 6/20 0.45
CACNA1G O43497 2/20 0.43
CACNA1H O95180 2/20 0.43
CACNA1I Q9P0X4 1/20 0.43
BRD4 O60885 2/20 0.40
ALDH1A1 P00352 2/20 0.40
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2D6 P10635 1/20 0.40
CYP2C19 P33261 1/20 0.40
TRPV1 Q8NER1 1/20 0.39
TEAD1 P28347 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
DRD2 P14416 1/20 0.38
HTR2A P28223 1/20 0.38
HTR2C P28335 1/20 0.38
HTR2B P41595 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2979728 0.85 SIGMAR1 (0.45) SIGMAR1CACNA1GCACNA1HCACNA1IBRD4
SCHEMBL17075090 0.79 SIGMAR1 (0.37) SIGMAR1ALDH1A1
SCHEMBL1803544 0.79 CACNA1G (0.43) SIGMAR1CACNA1GCACNA1HCACNA1IBRD4
SCHEMBL1803543 0.79 CACNA1G (0.43) SIGMAR1CACNA1GCACNA1HCACNA1IBRD4
SCHEMBL1803541 0.79 CACNA1G (0.43) SIGMAR1CACNA1GCACNA1HCACNA1IBRD4
SCHEMBL17138591 0.79 ALDH1A1 (0.51) SIGMAR1ALDH1A1L3MBTL1DRD2HTR2A
SCHEMBL432343 0.77 SLC6A2 (0.47) SIGMAR1CACNA1GCACNA1HCACNA1IBRD4
SCHEMBL27740507 0.77 CACNA1G (0.48) SIGMAR1CACNA1GCACNA1HCACNA1IBRD4
SCHEMBL27741772 0.77 CACNA1G (0.45) CACNA1GCACNA1HCACNA1IBRD4TRPV1
SCHEMBL17075141 0.76 ALDH1A1 (0.39) ALDH1A1CYP2C19DRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3116873-B1 HEXAHYDRODIAZEPINOQUINOLINES CARRYING A CYCLIC RADICAL ABBVIE DEUTSCHLAND (DE) 2018-02-28 EP disclosed
US-20170158693-A1 HEXAHYDRODIAZEPINOQUINOLINES CARRYING A CYCLIC RADICAL ABBVIE DEUTSCHLAND (DE) 2017-06-08 US disclosed
US-9573950-B2 Substituted [1,4]diazepino[6,7,1-ij]quinolines as serotonin 5-HT2C receptor modulators ABBVIE DEUTSCHLAND GMBH & CO KG (DE) 2017-02-21 US disclosed
EP-3116873-A1 HEXAHYDRODIAZEPINOQUINOLINES CARRYING A CYCLIC RADICAL AbbVie Deutschland GmbH & Co. KG (DE) 2017-01-18 EP disclosed
US-20150259343-A1 HEXAHYDRODIAZEPINOQUINOLINES CARRYING A CYCLIC RADICAL AbbVie Deutschland GmbH & Co. KG (DE) 2015-09-17 US disclosed
WO-2015136090-A1 HEXAHYDRODIAZEPINOQUINOLINES CARRYING A CYCLIC RADICAL AbbVie Deutschland GmbH & Co. KG (DE) 2015-09-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170158693-A1 HEXAHYDRODIAZEPINOQUINOLINES CARRYING A CYCLIC RADICAL HTR2C, HTR2A, HTR5A SIGMAR1 204/4885CACNA1G 1036/4885CACNA1H 894/4885
US-20150259343-A1 HEXAHYDRODIAZEPINOQUINOLINES CARRYING A CYCLIC RADICAL HTR2C, HTR2A, HTR5A SIGMAR1 204/4885CACNA1G 1036/4885CACNA1H 894/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.